Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 3/2018

01-06-2018 | Pharmacologic Therapy (W.H.W. Tang, Section Editor)

Optimizing Cardiac Resynchronization Therapy: an Update on New Insights and Advancements

Authors: Adam Grimaldi, Eiran Z. Gorodeski, John Rickard

Published in: Current Heart Failure Reports | Issue 3/2018

Login to get access

Abstract

Purpose of Review

This review focuses on the current advancements in optimizing patient response to cardiac resynchronization therapy (CRT).

Recent Findings

It has been well known that not every patient will derive benefit from CRT, and of those that do, there are varying levels of response. Optimizing CRT begins well before device implant and involves appropriate patient selection and an understanding of the underlying substrate. After implant, there are different CRT device programming options that can be enabled to help overcome barriers as to why a patient may not respond.

Summary

Given the multifaceted components of optimizing CRT and the complex patient population, multi-subspecialty clinics have been developed bringing together specialists in heart failure, electrophysiology, and imaging. Data as to whether this results in better response rates and outcomes shows promise.
Literature
1.
Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol. 2002;39(2):194–201.CrossRefPubMed
2.
Rickard J, Cheng A, Spragg D, Bansal S, Niebauer M, Baranowski B, et al. Durability of survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: fate of “non-responders”. Heart Rhythm. 2014;11(3):412–6.CrossRefPubMed
3.
Rickard J, Michtalik H, Sharma R, Berger Z, Iyoha E, Green AR, et al. Predictors of response to cardiac resynchronization therapy: a systematic review. Int J Cardiol. 2016;225:345–52.CrossRefPubMed
4.
Birnie DH, Tang AS. The problem of non-response to cardiac resynchronization therapy. Curr Opin Cardiol. 2006;219:20–6.CrossRef
5.
Rickard J, Jackson G, Spragg DD, Cronin EM, Baranowski B, Tang WHW, et al. QRS prolongation induced by cardiac resynchronization therapy correlates with deterioration in left ventricular function. Heart Rhythm. 2012;9(10):1674–8.CrossRefPubMed
6.
Rickard J, Kumbhani DJ, Popovic Z, Verhaert D, Manne M, Sraow D, et al. Characterization of super-response to cardiac resynchronization therapy. Heart Rhythm. 2010;7(7):885–9.CrossRefPubMed
7.
Curtis AB, Worley SJ, Chung ES, et al. Improvement in Clin outcomes with biventricular versus right ventricular pacing: the BLOCK HF study. J Am Coll Cardiol. 2016;18:2148–57.CrossRef
8.
Rickard J, Kumbhani DJ, Gorodeski EZ, Baranowski B, Wazni O, Martin DO, et al. Cardiac resynchronization therapy in non-left bundle branch block morphologies. Pacing Clin Electrophysiol. 2010;33(5):590–5.CrossRefPubMed
9.
Wokhlu A, Rea RF, Asirvatham SJ, Webster T, Brooke K, Hodge DO, et al. Upgrade and de novo cardiac resynchronization therapy: impact of paced or intrinsic QRS morphology on outcomes and survival. Heart Rhythm. 2009;6:1439–47.CrossRefPubMed
10.
Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, et al. Effectiveness of cardiac Resyncrhonization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT). Circulation. 2011;123:1061–72.CrossRefPubMed
11.
Rickard J, Bassiouny M, Cronin EM, Martin DO, Varma N, Niebauer MJ, et al. Predictors of response to cardiac resynchronization therapy in patients with a non-left bundle branch block morphology. Am J Cardiol. 2011;108(11):1576–80.CrossRefPubMed
12.
Fantoni C, Kawabata M, Massaro R, et al. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three-dimensional non-fluoroscopic electroanatomic mapping system. J Cardiovasc Electrophysiol. 2005;16(2):112–9.CrossRefPubMed
13.
Varma N. Left ventricular conduction delays and relation to QRS configuration in patients with left ventricular dysfunction. Am J Cardiol. 2009;103(11):1578–85.CrossRefPubMed
14.
15.
Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association electrocardiography and arrhythmias committee, council on clinical cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53(11):976–81.CrossRefPubMed
16.
Strauss DG, Selvester RH, Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. Am J Cardiol. 2011;107(6):927–34.CrossRefPubMed
17.
Migliore F, Baritussio A, Stabile G, Reggiani A, D’Onofrio A, Palmisano P, et al. Prevalence of true left bundle branch block in current practice of cardiac resynchronization therapy implantation. J Cardiovasc Med. 2016;17(7):462–8.CrossRef
18.
Epstein AE, DiMarco JP, Ellenbogen KA, American College of Cardiology Foundation; American Heart Association task force on practice guidelines, Heart Rhythm Society, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device –based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61:6–75.CrossRef
19.
Kim J, Shin MS, Hwang SY, Park E, Lim YH, Shim JL, et al. Memory loss and decreased executive function are associated with limited functional capacity in patients with heart failure compared to patients with other medical conditions. Heart Lung. 2018;47(1):61–7.CrossRefPubMed
20.
Verbrugge FH, Dupont M, Rivero-Ayerza M, de Vusser P, van Herendael H, Vercammen J, et al. Comorbidity significantly affects clinical outcome after cardiac resynchronization therapy regardless of ventricular remodeling. J Card Fail. 2012;18(11):845–53.CrossRefPubMed
21.
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–66.CrossRefPubMed
22.
Hayes DL, Boehmer JP, Day JD, Gilliam FR III, Heidenreich PA, Seth M, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8(9):1469–75.CrossRefPubMed
23.
Singh JP, Klein HU, Huang DT, Reek S, Kuniss M, Quesada A, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT). Circulation. 2011;123(11):1159–66.CrossRefPubMed
24.
Wilton SB, Shibata MA, Sondergaard R, Cowan K, Semeniuk L, Exner DV. Relationship between left ventricular lead position using a simple radiographic classification scheme and long-term outcome with resynchronization therapy. J Interv Card Electrophysiol. 2008;23(3):219–27.CrossRefPubMed
25.
Gold MR, Birdersdotter-Green U, Singh JP, et al. The relationship between ventricular electrical delay and left ventricular remodeling with cardiac resynchronization therapy. Eur Heart J. 2011;32(20):2516–24.CrossRefPubMedPubMedCentral
26.
Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual chamber and VVI implantable defibrillator trial investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the dual chamber and VVI implantable defibrillator (DAVID) trial. JAMA. 2002;288(24):3115–23.CrossRefPubMed
27.
Boriani G, Kranig W, Donal E, Calo L, Casella M, Delarche N, et al. A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the biventricular versus left Univentricular pacing with ICD back-up in heart failure patients (B-LEFT HF) trial. Am Heart J. 2010;159(6):1052–8.CrossRefPubMed
28.
Martin DO, Lemke B, Birnie D, Krum H, Lee KL, Aonuma K, et al. Adaptive CRT study investigators. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm. 2012;9(11):1807–14.CrossRefPubMed
29.
• Tomassoni G, Baker J, Corbisiero R, et al. Rationale and design of a randomized trial to assess the safety and efficacy of MultiPoint Pacing (MPP) in cardiac resynchronization therapy: The MPP Trial. Ann Noninvasive Electrocardiol, 2017;22(6). https://​doi.​org/​10.​1111/​anec.​12448. This study is ongoing and will help to answer wether MPP results in improved CRT response rates.
30.
Kamath GS, Cotiga D, Koneru JN, Arshad A, Pierce W, Aziz EF, et al. The utility of 12-lead holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. J Am Coll Cardiol. 2009;53(12):1050–5.CrossRefPubMed
31.
• Plummer CJ, Frank CM, Bari Z, et al. A novel algorithm increases the delivery of effective cardiac resynchronization therapy during atrial fibrillation: the CRTee randomized crossover trial. Heart Rhythm. 2017;S1547-5271(17):31240–7. This study shows that with this novel algorithm, there is an increase in effective CRT pacing in patients with AF. More data is needed to see if this means improved response to CRT and clinical outcomes.
32.
Ellenbogen KA, Gold MR, Meyer TE, Fernndez Lozano I, Mittal S, Waggoner AD, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010;122(25):2660–8.CrossRefPubMed
33.
Boriani G, Muller CP, Seidl KH, et al. Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. The resynchronization for the HemodYnamic treatment for heart failure management II implantable cardioverter defibrillator (RHYTHM II ICD) study. Am Heart J. 2006;151(5):1050–8.CrossRefPubMed
34.
Weiss R, Malik M, Dinerman J, et al. VV optimization in cardiac resynchronization therapy non-responders: RESPONSE-HF trial results. Abstract AB12–5. Denber (CO): HRS. 2010.
35.
Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O'Halloran D, Elsik M, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy. J Am Coll Cardiol. 2012;59(17):1509–18.CrossRefPubMed
36.
Saba S, Marek J, Schwartzman D, Jain S, Adelstein E, White P, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy. Circ Heart Fail. 2013;6(3):427–34.CrossRefPubMed
37.
Mullens W, Grimm RA, Verga T, Dresing T, Starling RC, Wilkoff BL, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009;53(9):765–73.CrossRefPubMed
38.
Altman RK, Parks KA, Schlett CL, et al. Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes. Eur Heart J. 2012;17:2181–8.CrossRef
Metadata
Title
Optimizing Cardiac Resynchronization Therapy: an Update on New Insights and Advancements
Authors
Adam Grimaldi
Eiran Z. Gorodeski
John Rickard
Publication date
01-06-2018
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 3/2018
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-018-0391-y

Other articles of this Issue 3/2018

Current Heart Failure Reports 3/2018 Go to the issue

Pharmacologic Therapy (W.H.W. Tang, Section Editor)

Management of Sleep Disordered Breathing in Patients with Heart Failure

Management of Heart Failure (T. Meyer, Section Editor)

Essential Elements of Early Post Discharge Care of Patients with Heart Failure

Pharmacologic Therapy (W.H.W. Tang, Section Editor)

Contraceptive Strategies in Women With Heart Failure or With Cardiac Transplantation

Pharmacologic Therapy (W.H.W. Tang, Section Editor)

Novel Insights and Treatment Strategies for Right Heart Failure

Management of Heart Failure (T. Meyer, Section Editor)

Has the Time Come to Be More Aggressive With Bariatric Surgery in Obese Patients With Chronic Systolic Heart Failure?

Pharmacologic Therapy (W.H.W. Tang, Section Editor)

Nutritional Interventions in Heart Failure: Challenges and Opportunities

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits